💊 All medicines can cause side effects, but together, we can make them safer. Even after approval, medicines and vaccines are continuously monitored to ensure they remain safe and effective. We can all play an essential role in improving #PatientSafety by reporting any suspected side effects to our national medicines authority. This simple action helps make medicines safer for everyone and supports a culture of safety in healthcare. At Teamit, we’re proud to support #MedSafetyWeek, raising awareness about the importance of pharmacovigilance with Uppsala Monitoring Centre. Together, we can #PreventSideEffects and make a lasting impact on global #PatientSafety. 👉 Learn more about how you can contribute: https://loom.ly/7Dh1yM8
Teamit
Consultoría y servicios a empresas
Empowering collaborative research and innovation for a healthier future
Sobre nosotros
We are a research management organisation that builds strong public-private partnerships and provides transversal expertise for impactful health science. We bring in our knowledge in the areas of project and scientific management, communications, multi-stakeholder engagement, regulatory science, real world evidence, training and education, quality and risk management, sustainability and exploitation. Our team has long-term experience in European funded research projects (Horizon 2020, Horizon Europe, Innovative Medicines Initiative – IMI and Innovative Health Initiative – IHI) and multinational drug safety and pharmacoepidemiology research studies. We team up with partners from the entire health ecosystem to ideate and implement research and innovation initiatives. We work with academia, clinical centers, health industry, SMEs, patient and civil society organisations, regulatory, funding bodies, policy makers and regional or national authorities. If you share our vision and would like to join a dynamic organisation, keep an eye on our latest job offers.
- Sector
- Consultoría y servicios a empresas
- Tamaño de la empresa
- De 11 a 50 empleados
- Sede
- Barcelona
- Tipo
- De financiación privada
- Fundación
- 2020
Ubicaciones
-
Principal
Cómo llegar
Barcelona, ES
Empleados en Teamit
Actualizaciones
-
📄 Have you explored our latest White Paper? Teamit Institute recently published an in-depth resource on the critical role of scientific management in real-world evidence studies. This paper highlights the impact of well-structured study management on research outcomes. Hear insights from Study Manager Elena Palà Vila about the motivations driving this publication. Curious to learn more? Read the full White Paper here ➡️ [https://loom.ly/nDJhck4] #ScientificManagement #RealWorldEvidence #Pharmacovigilance #Teamit Gianmarco Di Mauro, PhD, Fabio Riefolo, PhD, Eva Molero Romen, Dana D., Anna Bonaterra Pastra, PhD, Anna Brutau Abia, Ph.D., Alba Ortega Flores, Irene Pazos
-
-
🚀 Exciting News! Teamit Institute Partners with Utrecht University to Strengthen EU PE&PV Research Network! 🚀 We are thrilled to announce that Teamit Institute has forged a strategic partnership with Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University at the Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, to streamline the European Pharmacoepidemiology & Pharmacovigilance (EU PE&PV) Research Network Network management and enhance coordination, particularly for upcoming European Medicines Agency tenders! 🤝 In this collaboration, Teamit Institute will play a crucial role in enhancing project management and coordination services, focusing on: 👥Communications: streamlining internal and external updates, including newsletters and EMA queries. 🌐Network Management: coordinating activities, maintaining connections, and providing regular updates to members. 🗞️Tender Support: leading the evaluation, proposal development, and submission logistics for upcoming EMA tenders. 📝Procurement Support: assisting with activities for a new Framework contract with the European Medicines Agency (EMA). 🔬Pharmacoepidemiology Studies Management: overseeing communications and deliverables and tracking study registration in the EMA-HMA catalogue, upon EMA project awards. This alliance marks a significant step forward in research coordination, and we are committed to advancing RWE research for better health outcomes across Europe. 🌍💡 Find out more about our new coordination alliance here ➡[https://loom.ly/y7ltdO8] #TeamitInstitute #EUPartnership #Pharmacoepidemiology #Pharmacovigilance #HealthcareInnovation #RWE
-
-
Last week, Teamit CEO Eva Molero Romen and Senior Project Manager Sarai Rodríguez Navarro joined the REMEDi4ALL and REPO4EU teams in Brussels to discuss' progress over the last 24 months. We’re excited to look ahead at upcoming milestones, challenges, and opportunities to collaborate on building a thriving drug repurposing community👥. Special thanks to REMEDi4ALL and REPO4EU representatives for your valuable insights and to REMEDi4ALL project officer Monica Ensini and the European Health and Digital Executive Agency (HaDEA) for your guidance and support in this journey🛤️.
-
-
📸 A few highlights from the ERDERA Kick-Off Meeting in Paris. It was an absolute pleasure to come together with representatives from over 170 organisations that are part of ERDERA, a brand news partnership championed by the European Union and member states. Together, we are working to advance research in the prevention, diagnosis, and treatment of rare diseases. #ERDERA #RareDiseases #Research Gisela Pairó, Òscar Cusó, Anna Llobet i Martí, Maica Llavero Hurtado, MPharm, Ph.D., Eva Molero Romen
-
-
Teamit ha compartido esto
I have participated in the launch of ERDERA this week in Paris 😍😍 It’s all about Rare Diseases: Better Prevention, Better Diagnosis, Better Treatment. This BIG European Alliance brings together more than 170 organisations to foster this transformation. I’m honoured to be part of this vibrant community. At Teamit we are supporting the Coordination Team on management aspects and leading the comminications strategy and implementation. We are excited to to start this journey 🤩🤩 Maica Llavero Hurtado, MPharm, Ph.D. Anna Llobet i Martí Gisela Pairó Òscar Cusó Freya Sentmartí Edwards Thank you Daria Julkowska for your inspiring leadership, all the INSERM Coordination Team colleagues and the Consortium partners 👏🏻👏🏻👏🏻
-
We had the opportunity to join ERDERA's Opening Ceremony live in Paris and follow inspirational speeches. Read summary below👇
🌟 ERDERA Opening Ceremony Highlights 🌟 We've just wrapped up an inspiring ERDERA opening ceremony with nearly 600 attendees joining online and in person in Paris. Here are some key takeaways from our distinguished speakers: 🔬 Nacer Boubenna, Scientific Director, Head of the Biology and Health Department (French Ministry of Higher Education and Research), emphasised the critical role of ERDERA in structuring the ecosystem to benefit patients: “ERDERA enables collaboration across diverse areas, ranging from research to innovation in diagnosis and care” 🌍 Anne-Sophie Lapointe (PhD), Head of Rare Disease Mission, Department to the Director General of Healthcare Provision (Direction générale de l'offre de soins (DGOS), reminded us that capacity building is essential for creating sustainable networks: “We possess the knowledge and tools to change the lives of millions affected by rare diseases. Let us commit today to shaping a future where no one is left behind”. 💡Irene Norstedt, Director, People Directorate DG RTD, European Commission, highlighted the EU's commitment to advancing rare disease research: “We have invested more than €3 billion in collaborative research over the past 20 years and this has translated into better diagnosis and the development of several new orphan medicines”. 🔧 Arjon Van Hengel , Deputy Head of Unit for Health Innovations & Ecosystems at the European Commission, noted that ERDERA's efforts could greatly progress health research in rare diseases and other fields by pioneering new approaches: “Key to ERDERA’s success are the 24 European Reference Networks (ERNs) and their valuable clinical expertise”. 👥 Virginie Bros-Facer, CEO, EURORDIS-Rare Diseases Europe, referred to the opportunity this new partnership brings to address fragmentation in clinical research: “The strength of ERDERA lies in its comprehensive and inclusive approach, uniting researchers, clinicians, industry partners, and most importantly, patients”. 💊 Guillaume Canaud, Hôpital Necker-Enfants malades AP-HP, shared his inspiring journey of repurposing a molecule originally developed against breast cancer to treat overgrowth syndromes: “From a single patient to a US FDA approved drug”. 💼 James Levine, President, Fondation Ipsen , discussed de-risking and funding strategies in rare diseases: “Patient associations are absolutely critical in rare diseases, but so are links with academia, industry, and regulatory bodies”. 🌟 Daria Julkowska, ERDERA coordinator, closed the event with a call to action: “Help us empower rare by making disease concrete and measurable” Thank you to all our speakers and participants for making this event a success! Read more about the event here: https://lnkd.in/dR-Z8DVX #ERDERA #RareDiseases #Research #Innovation #Healthcare European Health and Digital Executive Agency (HaDEA)
-
-
🌍 Today is #WorldStrokeDay, a crucial moment to raise awareness about a leading cause of death and disability. With more than 10 million stroke survivors across Europe, the effects are both significant and widespread. We are especially proud to support our partner, UMBRELLA_IHI, in their mission to revolutionise stroke care management through an innovative, data-driven approach. 🤝By working together, we’re moving closer to a future where stroke can be prevented and patients have access to better care. #StrokeAwareness #HealthcareInnovation #PatientCare #GreaterThan #Stroke Innovative Health Initiative (IHI) Vall d’Hebron Institute of Research (VHIR) - Vall d'Hebron Institut de Recerca, Siemens Healthineers, IRCCS Istituto Ortopedico Rizzoli, CERN, Stroke Alliance For Europe (SAFE), EATRIS, Bellvitge Biomedical Research Institute - IDIBELL, TrianecT, Nicolab, Allm EMEA, University Hospital Basel, AstraZeneca, Philips, Penumbra, Inc., Daiichi Sankyo, Carlos Molina, Frank Berger, Mira Katan, Hanno Herrmann
-
In #WorldStrokeDay, we join the community in raising awareness and shine a light on the #UMBRELLA project. Funded by the Innovative Health Initiative (IHI), and led by Dr. Carlos Molina from Vall d’Hebron Institute of Research (VHIR) - Vall d'Hebron Institut de Recerca and Frank Berger and Hanno Herrmann from Siemens Healthineers, UMBRELLA_IHI is set to revolutionise stroke care management.
🌍Today is World Stroke Day🧠 To mark this annual focal point for stroke awareness, we’ve created special features with experts at the forefront of transforming stroke care. 👉In this first feature, Carlos Molina, Head of the Stroke Research Group at Vall d’Hebron Institute of Research (VHIR) - Vall d'Hebron Institut de Recerca, underscores the critical role of data-driven approaches in shaping the future of stroke care. By leveraging data, we can significantly enhance treatment outcomes and improve patient care. Stay connected for more updates and breakthroughs. 🩺💪 Innovative Health Initiative (IHI), Siemens Healthineers, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Teamit , Amsterdam UMC, Erasmus MC, Universitätsklinikum Hamburg Eppendorf, KU Leuven, CERN, Nora Health, Stroke Alliance For Europe (SAFE), EATRIS, Bellvitge Biomedical Research Institute - IDIBELL, Instituto Pedro Nunes, EURECAT, Nacar Design, TrianecT, Nicolab, Allm EMEA, University Hospital Basel, AstraZeneca, Philips, The Janssen Pharmaceutical Companies of Johnson & Johnson, Neuravi , Actelion (now Janssen Pulmonary Hypertension), Penumbra, Inc., Daiichi Sankyo, Frank Berger, Hanno Herrmann, Mira Katan #WorldStrokeDay #GreaterThan #StrokeCare #AIInnovation #HealthcareRevolution #DigitalHealth #StrokeSurvivors #RealWorldData #HealthTech #UMBRELLAProject #StrokeAwareness
-
Teamit Institute is live at #WVCEU 2024 in Barcelona! 🌍 The World Vaccine Congress brings together leading experts to shape the future of Vaccine Research & Development across Europe and beyond. We’re proud that Teamit Institute’s Gianmarco Di Mauro, PhD and Fabio Riefolo, PhD contributed to a busy session on Real-World Evidence (RWE) in vaccines, chaired by Miriam Sturkenboom with the #VAC4EU working group 📄👥. This impactful session delved into EU-level challenges and opportunities in RWE for vaccine studies, looking ahead at what’s to come.💭📈 🌐 Looking forward to reconnecting with colleagues and engaging in valuable discussions throughout the rest of #WVC2024! With VAC4EU - Vaccine Monitoring Collaboration for Europe, Dana D., Alba Ortega Flores, Elena Palà Vila, Anna Bonaterra Pastra, PhD, Irene Pazos and Anna Brutau Abia, Ph.D.
-